MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA

大剂量放化疗在骨髓治疗中的应用 移植可以治愈一些恶性淋巴瘤患者 在常规化疗失败后。在这个项目中 我们建议更准确地确定患者的可治愈性 移植治疗首次复发或二次复发的恶性淋巴瘤 减刑。我们将调查疾病组织学的影响 异基因骨髓对治疗结果的影响。患有老年痴呆症的患者 有胸部放射病史的人有很高的风险 我们的标准CY-TBI后发生间质性肺炎 方案，对于这组人，我们建议测试一种化疗- 只有准备疗法。其他新的准备方案(AS (见第I.A.及I.B.节概述)将在患者身上进行测试 移植治疗顽固性疾病。最后，我们将比较 有望获得最好的骨髓移植 首次化疗后复发患者的抢救化疗 直线化疗。

The use of high dose chemoradiotherapy followed by marrow transplantation can cure some patients of malignant lymphoma after they have failed conventional chemotherapy. In this project we propose to determine more precisely the curability of patients transplanted for malignant lymphoma at first relapse or second remission. We will investigate the influence of disease histology and allogeneic marrow on treatment outcome. Patients with a prior history of radiotherapy to the chest are at high risk to develop interstitial pneumonitis after our standard CY-TBI regimen, and for this group we propose to test a chemotherapy- only preparative regimen. Other new preparative regimens (as outlined in sections I.A. and I.B.) will be tested in patients transplanted for refractory disease. Finally, we will compare prospectively marrow transplantation to the best available salvage chemotherapy in patients who have relapsed after first line chemotherapy.